PRN 2246

Drug Profile

PRN 2246

Alternative Names: PRN2246

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Principia Biopharma
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis
  • Preclinical Autoimmune disorders; CNS disorders; Inflammation

Most Recent Events

  • 09 Nov 2017 PRN-2246 licensed to Sanofi worldwide
  • 09 Nov 2017 Phase-I clinical trials in Multiple sclerosis (In volunteers) in Australia (PO) (ACTRN12617001457336; 9226649)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top